CorMedix Inc (CRMD) 옵션

So the big question is now, have they shaken off the huge short share count that kept showing
up on Yahoos Finance page for a many months.. IE, is it free to reflect what the business is
actually doing and get a share price reflective of it. TBD'd

A pretty good investment call with Needham.. Worth listening to from April 8th.
My take away is that I expected the end users would be actively pursuing the use of
CRMDs development cause it can save lives, save money if a CBRSI is prevented.
But it appears the uptick is slower than I was expecting and might be due to the end
users wondering if it really does what they say it can do. IE, a bit of caution involved.
CEO says that he expects as some adopt and the word gets out its 'working' as advertised,
it will lead to others (reluctance/hesitancy) to adopt as well.
Anyways, given the potential growth trajectory, this is looking like a much longer hold than
I was planning on doing (you ever get one that you take profits on too early?? and miss out
on a lot more if you had just been patient to let it play out??)

https://wsw.com/webcast/needham146/crmd/2238926

1. Outbreaks Linked to Dialysis and Catheters
Dialysis:
A 2022 CDC report documented a C. auris outbreak in a Texas dialysis center, where infections spread among patients using central venous catheters. The primary cause was traced to failure to follow sterilization protocols.
Dialysis patients are high-risk due to frequent use of invasive devices (e.g., catheters) and weakened immune systems from chronic kidney disease.

Catheters:
A 2020 study in Clinical Infectious Diseases found that 40% of U.S. C. auris infections were linked to invasive devices like central venous catheters or urinary devices.
A deadly 2019 outbreak in a Brooklyn, NY, ICU involved C. auris transmission via catheters and ventilators, resulting in 5 deaths.

2. Documented Legal Disputes
Illinois (2018): A patient died after contracting C. auris via a contaminated catheter. The family sued the clinic for negligent equipment hygiene.
New Jersey (2020): A long-term care facility faced a lawsuit after a dialysis patient developed C. auris from a non-sterile catheter. The case settled out of court.
California (2021): A healthcare facility confronted a class-action lawsuit over an outbreak tied to unsafe reuse of medical devices, including dialysis catheters.

3. Regulatory Actions
Florida (2021): A dialysis center was fined by CMS for violating infection-control standards after a C. auris outbreak.
The CDC issued updated guidelines for catheter management in high-risk patients, referencing failures in dialysis facilities.

6,38

https://www.thegatewaypundit.com/2025/03/cdc-sounds-alarm-hospital-workers-struggle-contain-urgent/

CANDIDA AURIS article

I figured long ago as a premise as to WHY it would gain
market share vs the lesser heparin was for this very reason:

you have a product that demonstrates it can reduce the chance of
a life threatening condition, you are going to want to reduce your odds
of lawsuits for....

Too bad there aren't lawsuits filed against shortsellers, hedge funds that use
their wealth to manipulate share prices..

Especially in a company like this one that has just had their first profitable qtr.
The share price should have been running except for the 2 hits it took that morn,
one in the pre and one on the open.

These lawyers should file class actions against hospitals!
Joe raises the price, you exploit the fears of those who have to decide the purchase!
If a patient develops a severe infection or dies, and it is discovered that a better solution existed but was not adopted, a lawsuit is not only possible but likely. In the United States, civil justice is quick to hold accountable those who fail to provide the best possible care, and settlements can be enormous.

In the U.S., every healthcare provider is well aware that effective tools exist to prevent infections. Given this awareness, it should be a patient’s right—and a healthcare system’s duty—to ensure access to the best available protection.

In the U.S., the concept of standard of care is crucial: if it is proven that a facility provided care below the generally accepted medical standards, it opens the door to a lawsuit.

Costs and damages for the patient ? A severe infection can lead to:
Longer hospital stays
Permanent damage
Loss of income
Additional medical expenses
Death

If a product (such as DefenCath) exists that reduces the risk of infections but was not used, a lawyer could argue that the hospital put the patient’s life at risk for financial reasons.

I would love to see a merge with EPIX! They are the right ones, they don't know what to develop and there is a lot to develop here!

science is good! I hope they can cover themselves well and quickly so they stop being a pain in the ass!

Candida auris is an emerging fungus that represents a serious global public health threat due to its resistance to multiple antifungal drugs and its ability to cause outbreaks in healthcare settings. First identified in Japan in 2009, it has rapidly spread internationally, with cases reported in numerous countries, including Italy.

The market for treatments targeting Candida auris infections is growing, reflecting the increasing incidence of infections and the need for effective therapies. According to a report, the global market for Candida auris infection treatment was valued at $1.01 billion in 2023 and is projected to reach $2.0 billion by 2032. This growth is attributed to the rising awareness of Candida auris infections and the increasing number of cases in healthcare settings, which drive demand for more effective diagnostic and therapeutic solutions.
— Market Research Future

Furthermore, the broader candidiasis therapeutics market, which includes treatments for various Candida infections, was valued at $4.5 billion in 2022 and is expected to reach $6.8 billion by 2030, with a compound annual growth rate (CAGR) of 5.5% from 2024 to 2030. This indicates a growing investment in the development of new antifungal agents and innovative therapies to combat Candida infections, including Candida auris.

OK, been around CRMD since around 2016.. This
reminds me of some chatter about them possibly pursuing a
cancer development, but it fell off my radar because of the focus on
the cath development.

Thanks for reminding me. Whats also interesting on their website?
No pipeline, no mention of their other developments. Focus is purely on
this effort to get Defencath adopted. They used to mention a few other
things like pursuing the oncology sector (caths).
Guessing that once their current effort starts to take on a life of tis own??

We may start to hear more from them such as the TPN effort thats about to start.

But anyways, this reminded me of somethings from 2018/2019 timeframe that I long
forgot about.

https://cormedix.com/cormedix-announces-publication-taurolidine-pre-clinical-oncology-data-investigational-new-drugs-journal/

https://cormedix.com/cormedix-inc-granted-orphan-drug-designation-taurolidine-treatment-neuroblastoma/?utm_source=chatgpt.com

First I have heard of the link to a possible cancer treatment.

I know they want to expand their use to caths in the oncology arena.

But this is really interesting news.

Got a link to it by chance. Thanks.

Taurolidine was originally developed to prevent infections. Today, it’s showing signs of antitumor activity.

Preclinical studies suggest it could act on MYC-driven tumors — neuroblastoma, lung, ovarian, lymphoma — among the most difficult to treat.

Developing these kinds of therapies is expensive. Very expensive.
But the potential is massive — and not just for investors. It's in everyone’s interest that promising molecules don’t get stuck halfway.
We must give things their proper value: this is good science, but it requires time, capital, and strategic vision.
And CorMedix has that vision. While looking ahead to oncology, it’s already building a cash-generating engine in the present.
DefenCath, a non-antibiotic solution based on taurolidine and heparin, is already FDA-approved for preventing catheter-related infections in dialysis patients.

The numbers?
$43 million in 2024 revenue, EBITDA > $12 million
Zero debt, $52 million cash
Price: $249 per vial
Contracts in place with 4 of the 5 largest U.S. dialysis providers
CMS reimbursement secured (TDAPA and NTAP)

In short, they’re self-funding.
And they’re expanding DefenCath into TPN, pediatrics, and oncology.
Once economies of scale kick in, this won’t be just a small biotech. It’ll be a case study.
The potential is huge. So is the strategy.
Time will tell who saw it early —
and hopefully, the shorts will cover before it's too late.

??? If you are talking selling CRMD for more TNXP? Nope, going to let this
playout. That earnings report was too good for what just happened. I still
suspect is a major short covering day is underway. Yahoo had somewhere
around 7 Mil shares short.. CRMD is at 15 Mil shares traded so far today.
Willing to bet the short count dropped 'some', and some of them are now
positioned 'long' for a rebound.

Some TNXP for CRMD? I really should consider some, only TNXP is a
longer term prospect for me.

sometimes its best to sit tight and let things settle down. And see what it 'gives'..

did you make the switch?

Should turn out to be a good buy with time.

Had a meeting this morn, just getting free.

But when I saw the premarket, warned someone that it looks
like a classic takedown was in the works for this morn..

Yahoo was still showing a heavy short position, this report
was POSITIVE, new target price is $18 (3/5 if I remember the date right)

and so a thinking the shorts had no choice but to hammer it this morn, scare
new buyers away. But its pretty clear now, the company has turned the corner
and its going to get harder to keep this hidden from the market. So expect to see
the short position slowly closed down while they try to hold the share price down.

Given that, yeah, think a buy now should be good for at least a 50% return, and if
the ones that have been screwing around with the share price ever stop?? Be nice to
see that $18 target price.

disclaimer: temped to sell 1/10th of my TNXP for some more shares but won't till
I see 'life' in CRMDs chart..

https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250318:nGNX7GcVsx&default-theme=true

I added a little!

Institutional holding % has actually (IF yahoos finance data is accurate)
increased from a long stagnant 32% to 40%..

Thats nice to see, long overdue and still wondering WHY its taken so long, WHY the
bigger players have left it alone while the reported short position remains high..

Even this morn, someone 'nailed' it right out of the gate..

Thought the earnings release was for 18 March, but now can't find
any PR on the date...

I wouldn't be surprised if someone ate it!

Blackrock reported to control 7.5% of the shares..

a 13G was filed on 5 Feb 2025.. Nice to see...

Can find it on CRMDs website under SEC filings..

Going to be interesting to see what it does when it releases its earnings/update.

(doesn't look like they have given a date yet for it) (last time they 'announced' on the 23rd

of Oct, then released on the 30th.. IF they follow that 'pattern'?? Maybe we hear something

this week?? Be nice to keep the chart from losing momentum, rolling over..

For there is still 7 Million shares reportedly SHORTED (over 10% of the outstanding).

Been tracking this number for many months now and it refuses to budge towards 5% for example.

And I can't come up with a good reason WHY it refuses to come down. Or WHY they are holding onto

a heavy short position. Although I suspect its because when things are 'quiet', they can easily hit it

when demand is weak, ak, how it got taken down to $8 for example.. Which they might be getting ready

to do now given the earnings isn't expected till?? (momentum/trend line rolling over, slight negative slope now)
 
Disclaimer: already sold around 1/2 of my shares on the first run up, but didn't get 'all' of that move..

CRMD 1 yr

Recent surprise update was nice to get and it was a good one.
Gave the share price some support.. Max Pain for Jan 17s OE
day is $9. While its not the 'serious' PAIN like
say TSLA has this month, it may (along with the bio sector under
pressure, see iBB, XBI) be helping to mute the markets response
to the recent news.

Disclaimer: sold Fridays $12 strike price covered calls on some of my shares. Made a
few thousand off of it. Would have sold CCs on all of my shares but the option market decided
to drop the price they were offering..

New contract announced yesterday. Wall Street reportedly
as of 8/15 is DOWN to 30% of the shares held by the
institutional players (down from 33% or so).
Tracking this number to see cause without WS
pushing the shares, buying the shares themselves, this
could be a rough ride to higher numbers.
For normally, an announcement like this would be at least
a 'minor' pop in the share price..

CRMD under $7

shares short # reportedly up to 19% of the outstanding

Institutional holdings have been running flat at roughly 32% for many months.

Has me wondering WHY wall street is seemingly not reacting to a company thats been approved
that has a product that is better for the end users than the current stand of care. Almost as if
they don't see it gaining market share or is it a case that some big pharma wants the product, cheap.
And therefore the share price is being kept tamped down by the short attacks and lack of institutional
buying that aids and abets the shorts efforts.

Stock price is show a lot weakness! I like to see it rally from here!

CorMedix Inc. Announces Commercial Agreement With Top Tier Dialysis Provider
BERKELEY HEIGHTS, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a multi-year commercial supply contract with a top tier midsized dialysis provider for the supply of DefenCath® (taurolidine and heparin).
https://www.yourcentralvalley.com/business/press-releases/globenewswire/9144311/cormedix-inc-announces-commercial-agreement-with-top-tier-dialysis-provider/

thanks rmgillis for sharing....greatly appreciated

Heparin is purely for patency. It has no effect on Catheter related bloodstream infections (CRSBIs). Defencath (formerly Neutrolin) includes heparin as one of its main constituent. Taurodoline is the anti-infective component in Defencath- it uniquely prevents biofilm which allows infections to gain a foothold in the bloodstream.. . In Europe TauroPharm (German company) sells a virtually identical catheter lock they call TauroLock. It was originally licensed to them by the predecessor company of Cormedix, BioLink. Because the catheter lock solution is deemed a "device" and not a drug in Europe as it is in the USA (courtesy of the FDA) it didn't have to go through the arduous FDA approval process. Cormedix was unable to stop TauroLock from continuing to sell their product without permission or royalty in the German courts. There are a number of copycats in Europe where the market entry barriers are much lower.

Now that CRMD has the exclusive FDA approval for the only catheter lock solution approved in the US, they will enjoy many years without competition. Once they have enough revenue they will commence an Oncology trial which has many times the market potential of the diabetes catheter lock solution market -- which is essentially new diabetes patients starting dialysis while they wait for maturation of an AV graft that will result in a fistula for further dialysis access. There are also always ESRD (end stage renal disease) patients who are not fistula candidates who must remain on catheters for all of their dialysis sessions - these unfortunate patients will need Defencath to protect their indwelling catheters from infection and biofilm for their remaining lifetimes. Life expectancy and quality of life with Defencath should be much better for these patients.

Well so much for $6 (LOL)...

And yep, it dropped down to meet its MA line, no surprise there..

And FYI, today is option expiration day. Max Pain for CRMD today is around $4.. Hmmm

But nice spike into the open on I suspect the TDAPA PR..

Be interesting to see how long it takes IV to get back up this time. Wondering WHY someone went after that message board..

But I digress. 1st of all, given the tendency for lawsuits to be filed for anything and everything anymore. The question on SOC would
appear to be a moot one. You have an APPROVED compound that works better than the current UNAPPROVED product (heparin). And
unless the cost in comparison to heparin is too big a differential? One would expect the targets of those lawsuits including their insurance
carriers would be saying, use the FDA approved one, use the one that has a better outcome profile and lets do the most we can to avoid unnecessary
infections and possible deaths that could occur with a lesser product.

2nd, on the reimbursement rate?? I wouldn't worry about it at this stage, let the cards get played out. There are unknowns, that time will clear up..

I agree with you also, and my post was not intended to suggest that I don't think it will be SOC or profitable or that a major player won't use. Just seems like we can't win here. Every positive gets flipped on its head. We get a good piece of news and almost always the "yeah, but..." crowd wins. until all the unkowns are known, it will be used as ammo against us longs. If they do announce the reimbursement amount, (and please god, I hope I am wrong, but I don't think that will come until June) they need to at least say they are in deep discussions with providers or nearing agreements with providers or at lease getting positive feedback from providers. I know we have a winner here. But for the life of me, I can't figure out why the institutions don't feel the same. I kind of thought we would be around 60 or 65% ownership by now. And I have a really hard time thinking I am smarter than they are.

I agree with you. If they don't know yet they should have just said it's under negotiation or something. They just left everyone hanging. I do think it will be SOC with TDAPA though. No matter what the pricing is it will still increase revenue for any provider while at the same time reduce infection rates. They are judged by CMS on infection rates and rewarded or punished accordingly so they will all want it.

I don't comment much over there, but I watch and listen. You all are super smart and knowledgeable, and I am just a little guy. I saw the PR and quickly skimmed looking for the reimbursement amount. When I didn't see it, I read it, thinking I missed it. I don't think anything nefarious is going on, but that is a huge missing piece that leaves the door open for negative thoughts and provides an opportunity for others to push it down. We all think it should be SOC, but at this point, it is not. We know it will be reimbursed, but we do not know how much other than CMS is pretty cheap, so who really knows. We know Frensius and Davita are the 2 major players, but we have no confirmation they will buy. Everything looks good, and the puzzle is coming together, but without knowing how much they can make and who has agreed to buy, it just leaves too much room for skepticism. I have been here for 7 years, and I am usually very calm and patient, but I am really frustrated today. I'm so tired of waiting for the next catalyst only to be let down. Sorry for the negatively - it's not usually my thing and I am holding. GL

Anyone here from IV? Wondering your thoughts on no reimbursement rate mentioned for TDAPA news

Time for a 'pause'?? Be happy if it could hold over $6+ while its Moving Average line which got 'lost' catches up..

Gets too far apart and its interesting to see how the share price and MA line seem to want to get back together. And unfortunately, it usually involves the share price being dragged lower..

Disclaimer: finally getting the move we have been looking for. 1st target price: $14 (hemo sector), 2nd target price: $25 (IF they can get the oncology sector)

CRMD new 52 hi

Its all about MARKET CAP vs potential revenues.

Some of us who have been in this for a long time had a market cap of around $600 Million based on 'conservative' guesses for sales/pricing.
Gave me a target price of around $25-30 or so BEFORE the 1-5 r/split, with only 25 Mil or so shares outstanding post the 1-5. But now thanks to the dilution to raise cash, a share count of around 58 Million? Now my target price is down to around $14..

So while a 1-5 r/split has occurred, dilution that doubled the number of outstanding shares took place, the MARKET CAP that we 'guessed' at way back around 2016-2017 hasn't changed, won't change until the company/anal-ysts shed some more light on how things are going, and the anal-ysts update their revenue/profits and market cap 'expectations'..

So yeah, it has room to 'run' to the target price, thanks to the 2 frigging CRLS, the damage done has been to the target price expectations thanks to the dilution..
Good luck..

$CRMD 6 is still only 1.20 pre split
We got more room to run
Keep the positive news flowing Joe

Nice follow through on news breaking 5

https://stocktwits.com/newinvestor07/message/568773658

RMB. well little chance of hurricanes in the NW ..:--). Hope it works out for you .
As you know my wife is a Nephrology PA . She handles catheter infections roughly once every 2-3 months . The biggest demand for CRMD's product is likely to be in the roughly 25,000 cases I think of emergency dialysis in a hospital setting each year ...rather than in the routine dialysis clinic setting .

We are more interested in UNCY and ARDX for treating high serum phosphorus. Most of my wife's patients can not get to goal on the current meds ...pill burden and they hate the taste . ARDX has developed a pill taken twice a day but 50% experience diarrhea getting used to the drug. UNCY has developed a " condensed " version of an existing binder thats 1 pill a day with meals ..swallowed .
FDA has delayed approval requesting a tolerability trial with dialysis patients

https://ir.unicycive.com/news/detail/55/unicycive-therapeutics-reaches-alignment-with-the-fda-on

Respond to me on the UNCY board if you want more details

Kiwi

How big is the sales team and infrastructure supposedly trying to sell this in Europe compared to the organization they have in the U.S.?

Yep still here Kiwi. Have been totally distracted with this move to Pac NW.

If they can't sell it in the EU in any volume , what makes you think they will do any better in the US ?
Kiwi

By all means, the company faces a binary event now as it did in 2019 (when this article is from). However, I don't see how the article you refer to brings any information of value at the companys current situation.

https://nightmarketresearch.com/cormedix-infected-with-hype-valuation-swollen/

Kiwi